- Adjusted EBITDA for the quarter was $522 million, representing a 32.7% margin; year-to-date adjusted EBITDA was $1 billion with a 32.4% margin.
- Adjusted gross margin was 61.7% for Q2, slightly down from 62% in Q2 2024, impacted by pricing pressures and foreign exchange effects.
- Debt reduction efforts included $350 million principal repayment and repurchase of $242 million of notes, resulting in a net leverage ratio expected below 4x by year-end.
- Free cash flow before onetime costs was $525 million in the first half of 2025, ahead of prior year, supported by working capital management and lower interest expense.
- Onetime costs related to restructuring and manufacturing separation are tracking to the midpoint of the $250 million to $300 million revised estimate for 2025.
- Organon reported second quarter 2025 revenue of $1.6 billion, down 1% at constant currency, primarily due to loss of exclusivity (LOE) of Atozet in the EU.
- Volume growth of 5.6% in the quarter was driven by fertility, Hadlima, Emgality, and Vtama.
Related items and other data are not available for this feed item.
Dafinchi